BIOPHYTIS American Depositary Share Repr 10 Shs Aktie [WKN DE: A2PNTA / ISIN: US09076G1040]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu BIOPHYTIS American Depositary Share Repr 10 Shs

30.09.24		Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities (EQS Group)
22.07.24		Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia (EQS Group)
11.07.24		Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity (EQS Group)
01.07.24		Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris (EQS Group)
20.06.24		Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million (EQS Group)
20.06.24		Biophytis extends its contract with Atlas to secure financing for its business activities (EQS Group)
12.06.24		Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens (EQS Group)
10.06.24		Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity (EQS Group)
07.06.24		Combined General Meeting of June 24, 2024 (EQS Group)
14.05.24		Biophytis announces the design of its phase 2 OBA clinical study in obesity (EQS Group)
29.04.24		Biophytis is deploying its partnership strategy in obesity (EQS Group)
24.04.24		Biophytis Announces Transfer of ADSs to OTC Market (EQS Group)
19.04.24		Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program (EQS Group)
18.04.24		Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity (EQS Group)
08.04.24		Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) (EQS Group)
04.04.24		RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 (EQS Group)
22.03.24		Biophytis presented its phase 3 protocol in the treatment of sarcopenia (EQS Group)
17.11.23		Biophytis announces receipt of Nasdaq Notice (EQS Group)
30.10.23		Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (BIO101) in Brazil (EQS Group)
27.10.23		Biophytis receives notice of delisting from Nasdaq and announces it will request a hearing before the Nasdaq Hearings Panel (EQS Group)
27.09.23		Biophytis releases its half-yearly accounts as of 30 June 2023 and provides an update on its operations (EQS Group)
25.09.23		Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101) (EQS Group)
19.09.23		Biophytis provides an update on its early access programs for Sarconeos (BIO101) in the treatment of severe forms of COVID-19 (EQS Group)
14.09.23		Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer (EQS Group)
11.09.23		Biophytis obtains FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia (EQS Group)
04.09.23		Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York (EQS Group)
16.08.23		Biophytis announces next regulatory steps in Europe and the United States for its COVA project (EQS Group)
08.08.23		Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe (EQS Group)
20.07.23		Biophytis: Biophytis has requested a pre-submission meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the treatment of COVID-19 (EQS Group)
19.07.23		Biophytis Announces $3.8 Million Registered Direct Offering (EQS Group)
18.07.23		Biophytis and SEQENS sign a partnership to produce Sarconeos (BIO101) active compound (EQS Group)
10.07.23		Biophytis has filed with the FDA for authorization to initiate SARA-31 phase 3 study in sarcopenia (EQS Group)
19.06.23		Biophytis reports clinical results for Sarconeos (BIO101) in sarcopenia treatment at the 16th SCWD International Congress (EQS Group)
16.06.23		Biophytis: RESULTS OF THE ANNUAL GENERAL MEETING ON JUNE 16, 2023 ALL RESOLUTIONS PRESENTED BY THE COMPANY HAVE BEEN ADOPTED (EQS Group)
05.06.23		Biophytis to participate at the BIO International Convention in Boston from the 5th to the 8th of June (EQS Group)
26.05.23		Biophytis has filed with the French National Authority for Health (HAS) an application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the treatment of severe forms of COVID-1 (EQS Group)
25.05.23		Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference (EQS Group)
15.05.23		Biophytis has filed with the EMA for authorization to initiate SARA-31 phase 3 study in sarcopenia (EQS Group)
11.05.23		Successful capital increase for Biophytis with 2.3 million raised (EQS Group)
10.05.23		Biophytis launches a round of fundraising for approximately 2 million euros (EQS Group)
09.05.23		Biophytis has requested a pre-submission meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the treatment of COVID-19 (EQS Group)
02.05.23		Biophytis strengthens its management team (EQS Group)
28.04.23		Biophytis announces receipt of Nasdaq Notice (EQS Group)
19.04.23		Biophytis regains compliance with NASDAQ minimum bid price requirement (EQS Group)
18.04.23		Biophytis Announces 2022 Financial Results and 2023 Perspectives (EQS Group)
17.04.23		Biophytis: Results of the Combined General Meeting on April 17, 2023 (EQS Group)
30.03.23		Biophytis: The Combined General Meeting will be held on second call on April 17, 2023 (EQS Group)
27.03.23		Biophytis: Biophytis presented Sarconeos (BIO101) as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Resea (EQS Group)
17.03.23		Biophytis announces ratio change under its American Depositary Receipt (ADR) program (EQS Group)
09.03.23		Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference (EQS Group)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

NVIDIA vor Q3-Ergebnissen: Hohe Erwartungen und höhere Kursziele für den KI-Giganten

Ripple explodiert – Jetzt investieren und Millionär werden?

Diese Aktien befinden sich Q3 2024 im Portfolio von Warren Buffett

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

thyssenkrupp-Aktie zieht dennoch an: thyssenkrupp mit weiterem Milliardenverlust

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	21.11.2024 19:55
Kaufwert:	EUR
	Hinzufügen Speichern